Brief: Expres2ion Initiates Research Collaboration With Evaxion

ExpreS2ion Biotech Holding AB

06/12/2022 07:14

Dec 6 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * EXPRES2ION AND EVAXION INITIATE RESEARCH COLLABORATION ON
A
NOVEL CYTOMEGALOVIRUS (CMV) VACCINE CANDIDATE
    * COLLABORATION TO COMBINE CO'S EXPRES2 PLATFORM, RESOURCES
FOR
VACCINE DEVELOPMENT AND PRODUCTION WITH EVAXION'S ARTIFICIAL
INTELLIGENCE PLATFORM
    * AIM IS TO, BEFORE END OF 2025, DEVELOP NOVEL CMV LEAD
VACCINE
CANDIDATE
    * HAS EXCLUSIVE RIGHT TO LICENSE THE VACCINE CANDIDATE UNDER
POTENTIAL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
    * RESEARCH COSTS AND IP LICENSING FOR COLLABORATION PROJECT
WILL
BE DIVIDED 50/50
    * ALL COSTS EXPECTED TO BE COVERED BY EACH PARTY'S EXISTING
BUDGET

Source text for Eikon:  ID:nWkr1sv8cW 
Further company coverage:  EXPRS2.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))